产品
编 号：F310510
分子式：C18H22N2O3S2
分子量：378.51
分子式：C18H22N2O3S2
分子量：378.51
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 300353-13-3
产品详情
生物活性：
RO-28-1675 is a potent allosteric glucokinase (GK) activator with an EC50 of 54 nM. RO-28-1675 can be used for the research of type 2 diabetes.
体内研究：
RO-28-1675 (50 mg/kg; p.o.) reduces blood glucose levels in wild-type C57BL/6J mice.RO-28-1675 exhibits high oral bioavailability (mice 92.8%) and Cmax (1140 μg/mL) following oral administration (10 mg/kg).Animal Model:10 weeks old male C57BL/6J mice
Dosage:50 mg/kg
Administration:Oral administration
Result:Reduced blood glucose levels.
Animal Model:C57BL/6J mice
Dosage:10 mg/kg (Pharmacokinetic Analysis
Administration:Oral administration
Result:Oral bioavailability (92.8%), Cmax (1140 μg/mL), T max (3.3 h).
体外研究：
RO-28-1675 can reverse the inhibitory action of the human glucokinase regulatory protein (GKRP).
RO-28-1675 is a potent allosteric glucokinase (GK) activator with an EC50 of 54 nM. RO-28-1675 can be used for the research of type 2 diabetes.
体内研究：
RO-28-1675 (50 mg/kg; p.o.) reduces blood glucose levels in wild-type C57BL/6J mice.RO-28-1675 exhibits high oral bioavailability (mice 92.8%) and Cmax (1140 μg/mL) following oral administration (10 mg/kg).Animal Model:10 weeks old male C57BL/6J mice
Dosage:50 mg/kg
Administration:Oral administration
Result:Reduced blood glucose levels.
Animal Model:C57BL/6J mice
Dosage:10 mg/kg (Pharmacokinetic Analysis
Administration:Oral administration
Result:Oral bioavailability (92.8%), Cmax (1140 μg/mL), T max (3.3 h).
体外研究：
RO-28-1675 can reverse the inhibitory action of the human glucokinase regulatory protein (GKRP).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备